We aim to estimate the diagnostic performances of anterior gradient homolog-2 ( AGR2) and Leucine-rich repeat-containing-G-protein-coupled receptor 5 ( LGR5) in peripheral blood (PB) as mRNA biomarkers in colorectal cancer (CRC) and to explore their prognostic significance. Real-time PCR was used to analyze AGR2 and LGR5 in 54 stages I-IV CRC patients and 19 controls. Both mRNAs were significantly increased in PB from CRC patients compared to controls. The area under the receiver-operating characteristic curves were 0.722 ( p = 0.006), 0.376 ( p = 0.123) and 0.767 ( p = 0.001) for AGR2, LGR5 and combined AGR2/LGR5, respectively. The AGR2/LGR5 assay resulted in 67.4% sensitivity and 94.7% specificity. AGR2 correlated with pT3–pT4 and high-grade tumors. LGR5 correlated with metastasis, R2 resections and high-grade. The progression-free survival (PFS) of patients with high AGR2 was reduced ( p = 0.037; HR, 2.32), also in the stage I-III subgroup ( p = 0.046). LGR5 indicated a poor prognosis regarding both PFS ( p = 0.007; HR, 1.013) and overall survival ( p = 0.045; HR, 1.01). High AGR2/LGR5 was associated with poor PFS ( p = 0.014; HR, 2.8) by multivariate analysis. Our findings indicate that the assessment of AGR2 and LGR5 in PB might reflect the presence of circulating tumor cells (CTC) and stem cell like CTC in CRC. Increased AGR2 and LGR5 are associated with poor outcomes.
References
[1]
Malvezzi, M.; Arfé, A.; Bertuccio, P.; Levi, F.; La Vecchia, C.; Negri, E. European cancer mortality predictions for the year 2011. Ann. Oncol 2011, 22, 947–956.
[2]
Bustin, S.A.; Mueller, R. Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer. Mol. Asp. Med 2006, 27, 192–223.
[3]
Sergeant, G.; Penninckx, F.; Topal, B. Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood—A systematic review. J. Surg. Res 2008, 150, 144–152.
[4]
Rahbari, N.N.; Aigner, M.; Thorlund, K.; Mollberg, N.; Motschall, E.; Jensen, K.; Diener, M.K.; Büchler, M.W.; Koch, M.; Weitz, J. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterology 2010, 138, 1714–1726.
[5]
Tsouma, A.; Aggeli, C.; Lembessis, P.; Zografos, G.N.; Korkolis, D.P.; Pectasides, D.; Skondra, M.; Pissimissis, N.; Tzonou, A.; Koutsilieris, M. Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J. Gastroenterol 2010, 16, 5965–5974.
[6]
Thorsteinsson, M.; Jess, P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer. A review. Eur. J. Surg. Oncol 2011, 37, 459–465.
[7]
Iinuma, H.; Watanabe, T.; Mimori, K.; Adachi, M.; Hayashi, N.; Tamura, J.; Matsuda, K.; Fukushima, R.; Okinaga, K.; Sasako, M.; et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J. Clin. Oncol 2011, 29, 1547–1555.
[8]
Valladares-Ayerbes, M.; Díaz-Prado, S.; Reboredo, M.; Medina, V.; Iglesias-Díaz, P.; Lorenzo-Pati？o, M.J.; Campelo, R.G.; Haz, M.; Santamarina, I.; Antón-Aparicio, L.M. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect. Prev 2008, 32, 236–250.
[9]
Valladares-Ayerbes, M.; Díaz-Prado, S.; Reboredo, M.; Medina, V.; Lorenzo-Pati？o, M.J.; Iglesias-Díaz, P.; Haz, M.; Pértega, S.; Santamarina, I.; Blanco, M.; et al. Evaluation of plakophilin-3 mRNA as a biomarker for detection of circulating tumor cells in gastrointestinal cancer patients. Cancer Epidemiol. Biomark. Prev 2010, 19, 1432–1440.
[10]
Smirnov, D.A.; Zweitzig, D.R.; Foulk, B.W.; Miller, M.C.; Doyle, G.V.; Kenneth, J.P.; Neal, J.M.; Louis, M.W.; Steven, J.C.; Jose, G.M.; et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005, 65, 4993–4997.
[11]
Sieuwerts, A.M.; Mostert, B.; Bolt-de Vries, J.; Peeters, D.; de Jongh, F.E.; Stouthard, J.M.L.; Dirix, L.Y.; van Dam, P.A.; Galen, A.V.; de Vanja, W.; et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res 2011, 17, 3600–3618.
[12]
Thompson, D.A.; Weigel, R.J. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun 1998, 251, 111–116.
[13]
Pohler, E.; Craig, A.L.; Cotton, J.; Lawrie, L.; Dillon, J.F.; Ross, P.; Kernohan, N.; Hupp, T.R. The Barrett’s antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell Proteomics 2004, 3, 534–547.
[14]
Wang, Z.; Hao, Y.; Lowe, A.W. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008, 68, 492–497.
[15]
Park, S.W.; Zhen, G.; Verhaeghe, C.; Nakagami, Y.; Nguyenvu, L.T.; Barczak, A.J.; Killeen, N.; Erle, D.J. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. Proc. Natl. Acad. Sci. USA 2009, 106, 6950–6955.
[16]
Balic, M.; Lin, H.; Young, L.; Hawes, D.; Giuliano, A; McNamara, G.; Datar, R.H.; Cote, R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 2, 5615–5621.
[17]
Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11, doi:10.1186/bcr2333.
[18]
Visvader, J.E.; Lindeman, G.J. Cancer stem cells in solid tumors, accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8, 755–758.
[19]
Barker, N.; van Es, J.H.; Kuipers, J.; Kujala, P.; van den Born, M.; Cozijnsen, M.; Haegebarth, A.; Korving, J.; Begthel, H.; Peters, P.J.; et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449, 1003–1007.
[20]
McClanahan, T.; Koseoglu, S.; Smith, K.; Grein, J.; Gustafson, E.; Black, S.; Kirschmeier, P.; Samatar, A. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol. Ther 2006, 5, 419–426.
[21]
Uchida, H.; Yamazaki, K.; Fukuma, M.; Yamada, T.; Hayashida, T.; Hasegawa, H.; Kitajima, M.; Kitagawa, Y.; Sakamoto, M. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 2010, 101, 1731–1737.
[22]
Takahashi, H.; Ishii, H.; Nishida, N.; Takemasa, I.; Mizushima, T.; Ikeda, M.; Yokobori, T.; Mimori, K.; Yamamoto, H.; Sekimoto, M.; et al. Significance of Lgr5+ve Cancer Stem Cells in the Colon and Rectum. Ann. Surg. Oncol 2011, 18, 1166–1174.
[23]
K？hne, C.H.; Cunningham, D.; di Costanzo, F.; Glimelius, B.; Blijham, G.; Aranda, E.; Scheithauer, W.; Rougier, P.; Palmer, M.; Wils, J.; et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer, results of a multivariate analysis of 3825 patients. Ann. Oncol 2002, 13, 308–317.
[24]
DeLong, E.R.; DeLong, D.M.; Clarke-Pearson, D.L. Comparing the areas under two or more correlated receiver operating curves, a nonparametric approach. Biometrics 1988, 44, 837–845.
[25]
Taylor, J.M.G.; Ankerst, D.P.; Andridge, R.R. Validation of biomarker based risk prediction models. Clin. Cancer Res 2008, 14, 5977–5983.
[26]
Bustin, S.A.; Gyselman, V.G.; Siddiqi, S.; Dorudi, S. Cytokeratin 20 is not a tissue-specific marker for the detection of malignant epithelial cells in the blood of colorectal cancer patients. Int. J. Surg. Invest 2000, 2, 49–57.
[27]
Hundt, S.; Ulrike, H.; Brenner, H. Blood markers for early detection of colorectal cancer, a systematic review. Cancer Epidemiol. Biomark. Prev 2007, 16, 1935–1953.
[28]
Liu, D.; Rudland, P.S.; Sibson, D.R.; Platt-Higgins, A.; Barraclough, R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 2005, 65, 3796–3805.
[29]
Barraclough, D.L.; Platt-Higgins, A.; de Silva Rudland, S.; Barraclough, R.; Winstanley, J.; West, C.R.; Rudland, P.S. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am. J. Pathol 2009, 175, 1848–1857.
[30]
Zhang, Y.; Forootan, S.S.; Liu, D.; Barraclough, R.; Foster, C.S.; Rudland, P.S.; Ke, Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007, 10, 293–300.
[31]
Edgell, T.A.; Barraclough, D.L.; Rajic, A.; Dhulia, J.; Lewis, K.J.; Armes, J.E.; Barraclough, R.; Rudland, P.S.; Rice, G.E.; Autelitano, D.J. Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin. Sci. (Lond.) 2010, 118, 717–725.
[32]
Dong, A.; Gupta, A.; Pai, R.K.; Tun, M.; Lowe, A.W. The human adenocarcinoma-associated gene, AGR2, induces expression of amphiregulin through HIPPO pathway co-activator YAP1 activation. J. Biol. Chem 2011, 286, 18301–18310.
[33]
Merlos-Suárez, A.; Barriga, F.M.; Jung, P.; Iglesias, M.; Céspedes, M.V.; Rossell, D.; Sevillano, M.; Hernando-Momblona, X.; Silva-Diaz, V.; Mu？oz, P.; et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011, 8, 511–524.
[34]
de Sousa, E.; Melo, F.; Colak, S.; Buikhuisen, J.; Koster, J.; Cameron, K.; de Jong, J.H.; Tuynman, J.B.; Prasetyanti, P.R.; Fessler, E.; et al. Methylation of cancer-stem-cell-associated WNT target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011, 9, 476–485.
[35]
Pilati, P.; Mocellin, S.; Bertazza, L.; Galdi, F.; Briarava, M.; Mammano, E.; Tessari, E.; Zavagno, G.; Nitti, D. Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann. Surg. Oncol 2012, 19, 402–408.
[36]
Weitz, J.; Kienle, P.; Lacroix, J.; Willeke, F.; Benner, A.; Lehnert, T.; Herfarth, C.; von Knebel Doeberitz, M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin. Cancer Res 1998, 4, 343–348.
[37]
Peach, G.; Kim, C.; Zacharakis, E.; Purkayastha, S.; Ziprin, P. Prognostic significance of circulating tumor cells following surgical resection of colorectal cancers, a systematic review. Br. J. Cancer 2010, 102, 1327–1334.
[38]
Cohen, S.J.; Punt, C.J.; Iannotti, N.; Saidman, B.H.; Sabbath, K.D.; Gabrail, N.Y.; Picus, J.; Morse, M.; Mitchell, E.; Miller, M.C.; et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol 2008, 26, 3213–3221.
[39]
Tol, J.; Koopman, M.; Miller, M.C.; Tibbe, A.; Cats, A.; Creemers, G.J.; Vos, A.H.; Nagtegaal, I.D.; Terstappen, L.W.; Punt, C.J. Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol 2010, 21, 1006–1012.
[40]
Wicha, M.S.; Hayes, D.F. Circulating tumor cells, not all detected cells are bad and not all bad cells are detected. J. Clin. Oncol 2011, 29, 1508–1511.
[41]
Wittekind, C.; Greene, F.L.; Hutter, R.V.P.; Klimpfinger, M.; Sobin, L.H. TNM Atlas, 5th ed ed.; Springer-Verlag: Berlin, Germany, 2005.
[42]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2？ΔΔCt method. Methods 2001, 25, 402–408.
[43]
Pepe, M.S.; Etzioni, R.; Feng, Z.; Potter, J.D.; Thompson, M.L.; Thornquist, M.; Winget, M.; Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst 2001, 93, 1054–1061.
[44]
McShane, L.M.; Altman, D.G.; Sauerbrei, W.; Taube, S.E.; Gion, M.; Clark, G.M. Statistics subcommittee of the NCI-EORTC working group on cancer diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl. Cancer Inst 2005, 97, 1180–1184.
[45]
Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L.; et al. The MIQE guidelines, minimum information for publication of quantitative real-time PCR experiments. Clin. Chem 2009, 55, 611–622.
